Greenwich LifeSciences Inc. Company Profile
NASDAQ: GLSIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 16.41 -0.73%
Greenwich LifeSciences at a glance
Greenwich LifeSciences Inc. (NASDAQ: GLSI) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Stafford, TX. Greenwich LifeSciences is led by Mr. Snehal S. Patel. The company's shares have traded publicly since 2020.
At a market capitalization of $225.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001799788, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Greenwich LifeSciences do?
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Business description based on the company's public filings.
Company information
- Legal name
- Greenwich LifeSciences Inc.
- Ticker
- NASDAQ: GLSI
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Snehal S. Patel
- Headquarters
- Building 14, Stafford, TX, United States
- Phone
- 832-819-3232
- Website
- greenwichlifesciences.com
- IPO year
- 2020
- Market cap
- $225.90M
- SEC CIK
- 0001799788
- Latest annual report
- 10-K · Jun 1, 2026
Companies similar to Greenwich LifeSciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EVMNEvommune Inc. | 6.25 | -2.50% | $226.83M | vs GLSI |
| NATRNature's Sunshine Products Inc. | 12.64 | +0.56% | $222.41M | vs GLSI |
| AKBAAkebia Therapeutics Inc. | 0.8011 | -1.68% | $221.99M | vs GLSI |
| PRQRProQR Therapeutics N.V. | 1.63 | +3.82% | $230.02M | vs GLSI |
| SIONSionna Therapeutics Inc. | 4.90 | 0.00% | $221.24M | vs GLSI |
| ADCTADC Therapeutics SA | 1.73 | +8.80% | $220.87M | vs GLSI |
| TRDAEntrada Therapeutics Inc. | 5.67 | +2.53% | $220.77M | vs GLSI |
| SLGLSol-Gel Technologies Ltd. | 71.77 | +2.03% | $234.97M | vs GLSI |